etoposide + cyclophosphamide + carboplatin + cisplatin

This is a multi-agent chemotherapy combination consisting of four cytotoxic drugs: etoposide, cyclophosphamide, carboplatin, and cisplatin. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells: - **Etoposide** is a topoisomerase II inhibitor that induces DNA strand breaks by preventing the re-ligation of DNA during replication. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA strands, leading to cell death. - **Carboplatin** and **cisplatin** are platinum-based agents that form DNA adducts and crosslinks, inhibiting DNA synthesis and function. This combination does not have a widely recognized acronym or brand name in standard oncology regimens but represents an intensive cytotoxic protocol. It may be used in investigational settings or for specific high-risk malignancies where multiple mechanisms are targeted simultaneously. The regimen leverages the synergistic effects of these agents to maximize antitumor activity[1][3][5].